Adaptive Biotechnologies Corp
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
ADPT$30.26+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net loss | $(225,304) | $(200,368) | $(207,298) |
| Other comprehensive income (loss) | |||
| Change in unrealized gains and losses on investments | 4,331 | (2,979) | (2,030) |
| Comprehensive loss | (220,973) | (203,347) | (209,328) |
| Add: Comprehensive loss attributable to noncontrolling interest | 54 | 177 | 19 |
| Comprehensive loss attributable to Adaptive Biotechnologies Corporation | $(220,919) | $(203,170) | $(209,309) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.